1. Unprecedented Growth & Future Job Opportunity BIOTECHNOLOGY Dr. Sanjiv Kumar Maheshwari Professor and Dean, IFTM University, Moradabad

2. Biotechnology  Market and Growth Potential  Players  Opportunities  Why India

3. Courses offered by School of Biotechnology, IFTM University S No Course Duration (Years) Fee Per semester (RS.) Eligibility 1B. Tech. (Biotechnology)445000Minimum 45% (40% for SC/ST) at 10+2 with Physics, Chemistry, Mathematics / Biology 2B. Sc. (Biotechnology/Microbiology /Food Technology) 320000Minimum 45% (40% for SC/ST) at 10+2 with Physics, Chemistry, Mathematics / Biology 3M. Sc. (Biotechnology/Microbiology /Food Technology) 218000Minimum 50% (45% for SC/ST) at B.Sc. (Biotech.) / related Life Sciences 4M. Tech. (Biotechnology)241000Minimum 55% at B. Tech. (Biotechnology) 5Ph. D. (Biotechnology)230000As per latest UGC Norms

4. Biotech Market - Dynamic and growing  Size (2004-05) US$ 1090.5 mn  Largest segment Biopharma not to be confused with Pharma  Revenue from exports (2010-11) 56%  Total investment(2003-04) US$ 137 million Rate of growth over 202-2003 26%  Size (2010-11) US$ 4 Bn  Growth of Sector (2011-12) over 50% US$ 1 BN= 634 Crore

5. Bio Agri 6.95% Bio Pharma 75.24 % Bio Services 8.95% Bio-IT 2.09 % Biopharma leads the way Composition of Indian Biotech Sector (2004-05) Bio Industrial 6.74% Source:Biospectrum-ABLE Survey

6. Biotechnology as a Sector Third Largest Biotech Industry in Asia Pacific Region. Second Highest number of USFDA approved plants. US$ 3.7 BN to be spent on Biotechnology in India from 2012- 17. No. 1 producer of Hepatitis B Vaccine. US$ 4.3 BN Bioeconomy (earning from Biotechnology) by the end of 2015 US$ 200 BN Industry by 2025. US$ 1 BN= 634 Crore (Source: Make in India)

7. Market - A consistent uptrend 2002-03 2010 25% growth in investment 70% growth in employment 74% growth in R&D manpower 10% of global industry 1 million skilled jobs US$ 5 billion annual revenues Source: Confederation of Indian Industry (CII)

8. Indian Players

9. MNCs Scripting Success in India

10. Top MNCs World Wide RankCompanyCountry Market Cap in Q2 2015 (USD billion Market Cap in 2014 (USD billions 1Johnson & JohnsonUSA276.9277.8 2NovartisSwitzerland272.6229.8 3RocheSwitzerland240.4258.5 4PfizerUSA211.7205.4 5MerckUSA162.3166.9 6Novo NordiskDEN147.0125.4 7Gilead SciencesUSA145.1109.0 8SanofiFRA136.0138.1 9AmgenUSA117.793.1 10ActavisUSA116.738.2 11GlaxoSmithKlineGBR114.1128.9 12Bristol-Myers SquibbUSA105.097.6 13Biogen IdecUSA97.079.7 14AbbVieUSA91.7104.1 15CelgeneUSA90.489.5 16AstraZenecaGBR87.788.9 17Eli Lilly & CoUSA79.276.6 18Abbott LaboratoriesUSA69.967.9 19Valeant PharmaceuticalsCAN67.747.9 20Teva PharmaceuticalISR54.549.0

11. India: The Vaccine Hub Indian firms estimated to supply 90% of global demand for the measles vaccine, in the near future. Serum Institute, Pune is believed to be the world`s largest manufacturer of DPT vaccines. Indian Immunologicals operates the world`s second largest plant for veterinary vaccines and is also the world`s largest manufacturer of the vaccine against Foot and Mouth Disease.

12. Invest in Agri Biotech Biofertilisers GM Crops and seeds Biopesticides Biofuels Ag. Biotechnology

13. The India Advantage Trained manpower and knowledge base Rich biodiversity Extensive clinical trials opportunities Excellent network of research laboratories Well-developed base industries

14. The R & D Advantage Genetic Engineering DNA technologies New Drug Delivery Systems Rational drug design Stem cell research Bioinformatics Biotech R&D strengths spread across range of segments